Emergent Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EMERGENT
EMERGENT has three approved drugs.
There are five US patents protecting EMERGENT drugs.
Drugs and US Patents for Emergent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | 10,487,061 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Emergent | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Emergent Biodefense | TEMBEXA | brincidofovir | SUSPENSION;ORAL | 214460-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | 8,962,829 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Emergent Biodefense | TEMBEXA | brincidofovir | SUSPENSION;ORAL | 214460-001 | Jun 4, 2021 | RX | Yes | Yes | 9,303,051 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | 9,303,051 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EMERGENT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
International Patents for Emergent Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2581045 | ⤷ Start Trial |
| Japan | 6401820 | ⤷ Start Trial |
| European Patent Office | 3020720 | ⤷ Start Trial |
| Mexico | 2016006241 | ⤷ Start Trial |
| Eurasian Patent Organization | 031861 | ⤷ Start Trial |
| China | 105218580 | ⤷ Start Trial |
| Israel | 238217 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emergent Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

